"Mini" Transplant May Reverse Severe Sickle Cell Disease
Main Category: Blood / Hematology
Also Included In: Transplants / Organ Donations; Stem Cell Research; Clinical Trials / Drug Trials
Article Date: 10 Dec 2009 - 3:00 PST
email to a friend printer friendly view / write opinions rate article
Current Article Ratings:
Patient / Public:
Health Professional: 4.5 (2 votes)
Article Opinions: 0 posts
Results of a preliminary study by scientists at the National Institutes of Health and Johns Hopkins show that "mini" stem cell transplantation may safely reverse severe sickle cell disease in adults.
The phase I/II study to establish safety of the procedure, published December 10 in the New England Journal of Medicine, describes 10 patients with severe sickle cell disease who received intravenous transplants of blood-forming stem cells. The transplanted stem cells came from the peripheral blood of healthy related donors matched to the patients' tissue types.
Using this procedure, nine of 10 patients treated have normal red blood cells and reversal of organ damage caused by the disease.
Jonathan Powell, M.D., Ph.D., associate professor at the Johns Hopkins Kimmel Cancer Center, says the intravenous transplant approach for sickle cell disease, caused by a single mutation in the hemoglobin gene, does not replace the defective gene, but transplants blood stem cells that carry the normal gene.
Sickle cell disease, named for the "deflated" sickle-shaped appearance of red blood cells in those with the disease, hinders the cells' ability to carry oxygen throughout the body. In severe cases, it causes stroke, severe pain, and damage to multiple organs, including the lungs, kidneys and liver.
All patients in the study, ranging in age from 16 to 45, were treated at the NIH with what researchers call a non-myeloablative or "mini" transplant, along with an immune-suppressing drug called rapamycin.
Conventional transplant methods use high doses of chemotherapy to wipe out the immune system before the transplanted cells are injected, a process that has many side effects, including serious bacterial and fungal infections, which may kill some patients. In mini-transplants, lower doses of medication and radiation are used to make room for the donor's cells, the new source for healthy red blood cells in the patient.
According to Powell, side effects, including low white blood cell counts, were few and very mild compared with conventional bone marrow transplantation. But in nine of the 10, donor cells now coexist with the patients' own cells. One patient was not able to maintain the transplanted cells long term.
Minitransplants for sickle cell disease were tested in patients almost a decade ago, but were unsuccessful because the patients' immune systems rejected the transplanted cells, according to Powell, but by employing the drug rapamcyin, he says this new approach promotes the coexistence of the host and donor cells.
Powell's earlier research in mice showed that rapamycin inhibits an enzymatic pathway that suppresses the immune system and makes the host and donor cells tolerant to each other.
The NIH/Johns Hopkins team is conducting further studies on immune cells gathered from patients in their study, and looking at a combination of rapamycin with a well-known cancer drug called cyclophosphamide.
Other teams at Johns Hopkins are studying the use of half-matched donors for transplants in sickle cell patients, helping to widen the pool of potential donors for stem cell transplantation.
Funding for the study was provided by the National Institute of Diabetes, Digestive, and Kidney Diseases and the National Heart, Lung and Blood Institute at the NIH.
Study authors at the NIH include principal investigator John Tisdale, as well as Matthew Hsieh, Elizabeth Kang, Courtney Fitzhugh, M. Beth Link, Roger Kurlander, Richard Childs, and Griffin Rodgers.
Source: Johns Hopkins Medicine
Friday, December 11, 2009
Monday, May 18, 2009
Additional Links I found today
http://www.blackplanet.com/Sickle-Cell/
http://www.sicklecellart.com
http://www.sicklecellstamps.com/
http://www.sicklecellart.com
http://www.sicklecellstamps.com/
Wednesday, October 22, 2008
Link to Sickle Cell News release on www.marrow.org
Good Morning Friends,
Hope you are all well today. Below is a link with some very exciting news. Thanks to all of you and your continued support and efforts to “Save a Life” now even more people will receive a transplant.It is truly an honor to work with all of you.
Sue
Here is the link to the news release we sent out this week regarding the new sickle cell clinical trial. http://www.marrow.org/NEWS/News_Releases/2008/Sickle_Cell_Study.html
Wednesday, September 24, 2008
Xerox Corp Community Involvement Cooley’s Anemia Foundation of Monroe County
Cooley’s Anemia Foundation of Monroe County
Cooley's Anemia is a blood disorder. Our group raises funds to pay for medical treatment for those in need but can not afford the services. A percentage of the funds raised also goes to research for a Cure for Cooley’s as well as sickle cell and other blood disorders.
Volunteers are needed to help in fund-raisers and to staff the Bingo program for 1 hour per month or more if you are able.
EMPIRE BINGO HALL AT 380 EMPIRE BOULEVARD
http://www.thalassemia.org/sections.php?sec=3&cooleys_sess=3c3f7dc7aefcf2d3de7e37f2954b7d29
Shirley Cammilleri585-482-5587
Immediate and ongoing need
Cooley's Anemia is a blood disorder. Our group raises funds to pay for medical treatment for those in need but can not afford the services. A percentage of the funds raised also goes to research for a Cure for Cooley’s as well as sickle cell and other blood disorders.
Volunteers are needed to help in fund-raisers and to staff the Bingo program for 1 hour per month or more if you are able.
EMPIRE BINGO HALL AT 380 EMPIRE BOULEVARD
http://www.thalassemia.org/sections.php?sec=3&cooleys_sess=3c3f7dc7aefcf2d3de7e37f2954b7d29
Shirley Cammilleri585-482-5587
Immediate and ongoing need
Wednesday, August 6, 2008
Wednesday, July 30, 2008
Defining the mission statement
These questions are used to define the SC Group to have a good start in our communication
What is your vision (what do you want to be doing) for the SC Group?
- End of 2008 (short term)
- End of 2009 (long term)
- End of 2012 (future)
What are your goals(what do you want o accomplish) for the SC group?
The answers to these questions will form the mission statement that you can articulate and share with others
I will conduct research on SC and so will you. Your goal is to learn new information we can share. I will also do a situational (SWOT) Analysis on SC in general
Identify the people, audience you want to reach.
- For me it would be the government
- Educate family to become ambassador for the cause
- Educate friends to become ambassadors for the cause
What is your vision (what do you want to be doing) for the SC Group?
- End of 2008 (short term)
- End of 2009 (long term)
- End of 2012 (future)
What are your goals(what do you want o accomplish) for the SC group?
The answers to these questions will form the mission statement that you can articulate and share with others
I will conduct research on SC and so will you. Your goal is to learn new information we can share. I will also do a situational (SWOT) Analysis on SC in general
Identify the people, audience you want to reach.
- For me it would be the government
- Educate family to become ambassador for the cause
- Educate friends to become ambassadors for the cause
Subscribe to:
Posts (Atom)

